High-resolution mass spectrometry proteomics for the identification of candidate plasma protein biomarkers for chronic obstructive pulmonary disease

Biomarkers

Volumn 15, Issue 4, 2010, Pages 367-377

  York, Timothy P ^a   Van Den Oord, Edwin J C G ^a   Langston, Timothy B ^b   Edmiston, Jeffery S ^b   Mckinney, Willie ^b   Webb, Bradley Todd ^a,c   Murrelle, E Lenn ^c   Zedler, Barbara K ^c   Flora, Jason W ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Altria Client Services   (United States)

^c Venebio Group LLC   (United States)

Author keywords

Biomarker; Cigarette smoking; COPD; Mass spectrometry; Plasma; Protein

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CATION EXCHANGE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; FRACTIONATION; HUMAN; LIQUID CHROMATOGRAPHY; LUNG FUNCTION; MALE; MASS SPECTROMETRY; PATHOPHYSIOLOGY; PEPTIDE ANALYSIS; PROTEIN ANALYSIS; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY;

AGED; BIOLOGICAL MARKERS; BLOOD PROTEINS; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PEPTIDES; PROTEOME; PROTEOMICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 77952488210     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/13547501003789901     Document Type: Article

References (65)

1. Agusti A, MacNee W, Donaldson K, Cosio M. (2003). Hypothesis: does COPD have an autoimmune component? Torax 58:832-4.
2. Agusti A, Soriano JB. (2008). COPD as a systemic disease. COPD 5:133-8.
3. 1. The Lung Health Study. JAMA 272:1497-505.
4. Anthonisen NR, Connett JE, Murray RP. (2002). Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 166:675-9.
5. Barnes PJ, Shapiro SD, Pauwels RA. (2003). Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22:672-88.
6. Benjamini Y, Hochberg Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc B 57:289-300.
7. Bolger MS, Ross DS, Jiang H, Frank MM, Ghio AJ, Schwartz DA, Wright JR. (2007). Complement levels and activity in the normal and LPS-injured lung. Am J Physiol Lung Cell Mol Physiol 292: L748-59.
8. Bolton CE, Evans M, Ionescu AA, Edwards SM, Morris RH, Dunseath G, Luzio SD, Owens DR, Shale DJ. (2007). Insulin resistance and inflammation - a further systemic complication of COPD. COPD 4:121-6.
9. Carpenter SL, Mathew P. (2008). Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 14:1250-4.
10. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. (2004). The body-mass index airflow obstruction dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350:1005-12.
11. Choolani M, Narasimhan K, Kolla V, Hahn S. (2009). Proteomic technologies for prenatal diagnostics: advances and challenges ahead. Expert Rev Proteomics 6:87-101.
12. Chung KF. (2001). Cytokines in chronic obstructive pulmonary disease. Eur Respir J (Suppl. 34):50s-59s.
13. Elias JE, Gygi SP. (2007). Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nature Methods 4 (3):207-214.
14. Ezzati M, Lopez AD. (2003). Estimates of global mortality attributable to smoking in 2000. Lancet 362:847-52.
15. Fabbri LM, Luppi F, Beghe B, Rabe KF. (2008). Complex chronic comorbidities of COPD. Eur Respir J 31:204-12.
16. Fabbri LM, Rabe KF. (2007). From COPD to chronic systemic inflammatory syndrome? Lancet 370:797-9.
17. Fay WP, Garg N, Sunkar M. (2007). Vascular functions of the plasminogen activation system. Arterioscler Tromb Vasc Biol 27:1231-7.
18. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, Pilewski JM, Stoner MW, Csizmadia E, Zhang Y, Sciurba FC, Duncan SR. (2008). Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177:156-63.
19. Fu Q, Van Eyk JE. (2006). Proteomics and heart disease: identifying biomarkers of clinical utility. Expert Rev Proteomics 3:237-49.
20. Furie B, & Furie BC. (2005). Trombus formation in vivo. J Clin Invest 115:3355-62.
21. Hersh CP, DeMeo DL, Silverman EK. (2008). National Emphysema Treatment Trial state of the art: genetics of emphysema. Proc Am Torac Soc 5:486-93.
22. Hogg JC. (2006). Why does airway inflammation persist after the smoking stops? Torax 61:96-7.
23. Hou Y, Okada K, Okamoto C, Ueshima S, Matsuo O. (2008). Alpha2-antiplasmin is a critical regulator of angiotensin II-mediated vascular remodeling. Arterioscler Tromb Vasc Biol 28 (7):1257-62.
24. Ishii T, Matsuse T, Teramoto S, Matsui H, Hosoi T, Fukuchi Y, Ouchi Y. (2000). Association between alpha-1-antichymotrypsin polymorphism and susceptibility to chronic obstructive pulmonary disease. Eur J Clin Invest 30:543-8.
25. Jacot W, Lhermitte L, Dossat N, Pujol JL, Molinari N, Daures JP, Maudelonde T, Mange A, Solassol J. (2008). Serum proteomic profling of lung cancer in high-risk groups and determination of clinical outcomes. J Torac Oncol 3:840-50.
26. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, Katayama T, Kawashima S, Okuda S, Tokimatsu T, Yamanishi Y. (2008). KEGG for linking genomes to life and the environment. Nucleic Acids Res 36 (database issue): D480-4.
27. Kanehisa M, Goto S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27-30.
28. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita K F, Itoh M, Kawashima S, Katayama T, Araki M, Hirakawa M. (2006). From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34 (database issue): D354-7.
29. Karadag F, Karul AB, Cildag O, Yilmaz M, Ozcan H. (2008). Biomarkers of systemicinflammation in stable and exacerbation phases of COPD. Lung 186:403-9.
30. Kumar R, Singh VP, Baker KM. (2008). The intracellular renin-angiotensin system: implications in cardiovascular remodeling. Curr Opin Nephrol Hypertens 17:168-73.
31. Lalouel JM, Rohrwasser A, Terreros D, Morgan T, Ward K. (2001). Angiotensinogen in essential hypertension: from genetics to nephrology. J Am Soc Nephrol 12:606-15.
32. Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. (2005). Interleukin-1beta causes pulmonary inflammation emphysema and airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol 32:311-18.
33. Lee JM, Kang YR, Park SH, Cha SI, Kim JS, Kang HK, Lee WK, Kim MJ, Kim CH, Kim NS, Jung TH, Park JY. (2008). Polymorphisms in interleukin-1B and its receptor antagonist genes and the risk of chronic obstructive pulmonary disease in a Korean population: a case-control study. Respir Med 102:1311-20.
34. Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. (2007). Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 35:849-55.
35. Li X, Gong Y, Wang Y, Wu S, Cai Y, He P, Lu Z, Ying W, Zhang Y, Jiao L, He H, Zhang Z, He F, Zhao X, Qian X. (2005). Comparison of alternative analytical techniques for the characterisation of the human serum proteome in HUPO Plasma Proteome Project. Proteomics 5:3423-41.
36. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. (2002). Chronic obstructive pulmonary disease surveillance - United States 1971-2000. MMWR Surveill Summ 51:1-16.
37. Marcovina S, Packard CJ. (2006). Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 259:437-46.
38. Markiewski MM, Lambris JD. (2007). The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 171:715-27.
39. Meng Z, Veenstra TD. (2007). Proteomic analysis of serum plasma and lymph for the identification of biomarkers. Proteomics Clin Appl 1:747-57.
40. Navabi A, Mather DE, Bernier J, Spaner DM, Atlin GN. (2009). QTL detection with bidirectional and unidirectional selective genotyping: marker-based and trait-based analyses. Theor Appl Genet 118:347-58.
41. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, Apweiler R, Haab BB, Simpson RJ, Eddes JS, et al. (2005). Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5:3226-245.
42. Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B. (2007). Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Torax 62:595-601.
43. Poller W, Faber JP, Scholz S, Weidinger S, Bartholome K, Olek K, Eriksson S. (1992). Mis-sense mutation of alpha 1-antichymotrypsin gene associated with chronic lung disease. Lancet 339:1538.
44. Qin X, Swertfeger DK, Zheng S, Hui DY, Tso P. (1998). Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. Am J Physiol 274: H1836-40.
45. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. (2007). Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532-55.
46. Rahman I, Morrison D, Donaldson K, MacNee W. (1996). Systemic oxidative stress in asthma COPD and smokers. Am J Respir Crit Care Med 154:1055-60.
47. Ribeiro-Oliveira A, Jr, Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Simoes e Silva AC. (2008). The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag 4:787-803.
48. Rosenberg RD, Bauer KA. (1987). Trombosis in inherited deficiencies of antithrombin protein C and protein S. Hum Pathol 18:253.
49. Rosenzweig CN, Zhang Z, Sun X, Sokoll LJ, Osborne K, Partin AW, Chan DW. (2009). Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol 181:1407-14.
50. Sevenoaks M, J, & Stockley R. A. (2006). Chronic obstructive pulmonary disease inflammation and co-morbidity - a common inflammatory phenotype? Respir Res 7:70.
51. Soriano JB, Sin DD, Zhang X, Camp PG, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Petersson S, Postma DS, Szafranski W, Vestbo J. (2007). A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 131:682-9.
52. Stockley RA. (2007). Biomarkers in COPD: time for a deep breath. Torax 62:657-60.
53. Storey JD, Tibshirani R. (2003a). Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol Biol 224:149-57.
54. Storey JD, Tibshirani R. (2003b). Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100:9440-5.
55. Tapson VF. (2005). The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. Proc Am Torac Soc 2:71-7.
56. Tiengo A, Fadini GP, Avogaro A. (2008). The metabolic syndrome diabetes and lung dysfunction. Diabetes Metab 34:447-54.
57. van den Oord EJ. (2005). Controlling false discoveries in candidate gene studies. Mol Psychiatry 10:230-1.
58. Vivanco F, Martin-Ventura JL, Duran MC, Barderas MG, Blanco-Colio L, Darde VM, Mas S, Meilhac O, Michel JB, Tunon J, Egido J. (2005). Quest for novel cardiovascular biomarkers by proteomic analysis. J Proteome Res 4:1181-91. (Pubitemid 41208676)
59. Voelkel NF, Cool CD. (2003). Pulmonary vascular involvement in chronic obstructive pulmonary disease. Eur Respir J (Suppl. 46):28s-32s.
60. Voelkel NF, Douglas IS, Nicolls M. (2007). Angiogenesis in chronic lung disease. Chest 131:874-9.
61. Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF Jr, Lipinska I, O'Connor GT, Benjamin EJ. (2008). Systemic inflammation and COPD: the Framingham Heart Study. Chest 133:19-25.
62. Watson L, Vonk JM, Lofdahl CG, Pride NB, Pauwels RA, Laitinen LA, Schouten JP, Postma DS. (2006). Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study. Respir Med 100:746-53.
63. Wilk JB, Walter RE, Laramie JM, Gottlieb DJ, O'Connor GT. (2007). Framingham Heart Study genome-wide association: results for pulmonary function measures. BMC Med Genet 8 (Suppl. 1):S8.
64. Wouters EF, Creutzberg EC, Schols AM. (2002). Systemic effects in COPD. Chest 121 (Suppl.):127S-30S.
65. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. (2007). Systemic effects of smoking. Chest 131:1557-66.